Abstract:The human β1‐adrenergic receptor (β1AR) carries common (S49G) and rare (R31Q, A29T) single‐nucleotide polymorphisms (SNPs) in its extracellular N‐terminal domain. These were found to alter receptor O‐glycosylation and/or proteolytic cleavage, resulting in SNP‐dependent differences in β1AR cell surface expression and function that also involved the common C‐terminal R389G polymorphism. Thus, GPCR SNPs can modify receptor processing and function even when located outside well‐known domains that govern ligand binding and activation. N‐terminal nonsynonymous single‐nucleotide polymorphisms (SNPs) of G protein‐coupled receptors (GPCRs) are common and often affect receptor post‐translational modifications. Their functional implications are, however, largely unknown. We have previously shown that the human β1‐adrenergic receptor (β1AR) is O‐glycosylated in the N‐terminal extracellular domain by polypeptide GalNAc transferase‐2 that co‐regulates receptor proteolytic cleavage. Here, we demonstrate that the common S49G and the rare A29T and R31Q SNPs alter these modifications, leading to distinct effects on receptor processing. This was achieved by in vitro O‐glycosylation assays, analysis of native receptor N‐terminal O‐glycopeptides, and expression of receptor variants in cell lines and neonatal rat ventricular cardiomyocytes deficient in O‐glycosylation. The SNPs eliminated (S49G) or introduced (A29T) regulatory O‐glycosites that enhanced or inhibited cleavage at the adjacent sites (P52↓L53 and R31↓L32), respectively, or abolished the major site at R31↓L32 (R31Q). The inhibition of proteolysis of the T29 and Q31 variants correlated with increased full‐length receptor levels at the cell surface. Furthermore, the S49 variant showed increased isoproterenol‐mediated signaling in an enhanced bystander bioluminescence energy transfer β‐arrestin2 recruitment assay in a coordinated manner with the common C‐terminal R389G polymorphism. As Gly at position 49 is ancestral in placental mammals, the results suggest that its exchange to Ser has created a β1AR gain‐of‐function phenotype in humans. This study provides evidence for regulatory mechanisms by which GPCR SNPs outside canonical domains that govern ligand binding and activation can alter receptor processing and function. Further studies on other GPCR SNPs with clinical importance as drug targets are thus warranted.

Novel human α1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function

Altered O‐glycosylation of β1‐adrenergic receptor N‐terminal single‐nucleotide variants modulates receptor processing and functional activity

SNP Identification in Α_(2a)-Adrenergic Receptor Gene in Chinese and the Effect on Gene Expression

Alpha(1a)-Adrenergic Receptor Polymorphism And Vascular Response

Abstract 45: Deletion of a 4-Bp Noncoding Genomic Segment Orthologous to Human Rs1882961 Results in Sex-Divergent Changes in Salt-Induced Hypertension in Dahl Salt-Sensitive Rats

Alpha-adrenoceptor Gene Variants and Autonomic Nervous System Function in a Young Healthy Japanese Population.

Abstract 076: the Blood Pressure-associated Non-coding Single Nucleotide Polymorphism Rs28451064 Influences Gene Expression in Human Endothelial Cells

Alpha 1A-adrenergic receptor polymorphism and vascular response.

Abstract 040: Comparative Genomic Analysis and Functional Insights for Blood Pressure-Associated Single Nucleotide Polymorphisms

Variation in the Alpha2b-Adrenergic Receptor Gene (ADRA2B) and Its Relationship to Vascular Response in Vivo.

ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure

Species dependence of A3 adenosine receptor pharmacology and function

Trace amine associated receptor 1: predicted effects of single nucleotide variants on structure-function in geographically diverse populations

Polymorphisms Affecting Gene Transcription and Mrna Processing in Pharmacogenetic Candidate Genes: Detection Through Allelic Expression Imbalance in Human Target Tissues

A Common Beta(1)-Adrenergic Receptor Polymorphism (Arg389gly) Affects Blood Pressure Response To Beta-Blockade

Subtype-specific α1- and β-adrenoceptor signaling in the heart

Desensitization of vascular response in vivo: contribution of genetic variation in the [alpha]2B-adrenergic receptor subtype.

Desensitization of vascular response in vivo: contribution of genetic variation in the α2B-adrenergic receptor subtype:

Arg(389)Gly Beta(1)-Adrenoceptor Polymorphism Varies in Frequency among Different Ethnic Groups but Does Not Alter Response in Vivo

Association of β-adrenoceptor polymorphisms with cardiac autonomic modulation in Japanese males

Cancer-related somatic mutations alter adenosine A1 receptor pharmacology-A focus on mutations in the loops and C-terminus